Sugi Predict

Sugi Predict / Compounds / SCHEMBL9104569

SCHEMBL9104569

SCHEMBL9104569

Nc1ccn2nc(-c3ccccc3)nc2c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDE10A Q9Y233 3/20 0.54
▸ AHR P35869 1/20 0.51
▸ ADORA3 P0DMS8 5/20 0.43
▸ PARP1 P09874 1/20 0.42
▸ ALDH1A1 P00352 4/20 0.42
▸ HPGD P15428 4/20 0.42
▸ MEN1 O00255 3/20 0.42
▸ MAPT P10636 3/20 0.42
▸ KMT2A Q03164 3/20 0.42
▸ NPC1 O15118 2/20 0.42
▸ RAB9A P51151 2/20 0.42
▸ NR1H2 P55055 1/20 0.42
▸ NR1H3 Q13133 1/20 0.42
▸ CYP11B1 P15538 1/20 0.42
▸ CYP11B2 P19099 1/20 0.42
▸ KDM4E B2RXH2 2/20 0.41
▸ LMNA P02545 2/20 0.41
▸ EGFR P00533 1/20 0.41
▸ GLA P06280 1/20 0.41
▸ ADORA2A P29274 5/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL16341275 0.98 PDE10A (0.53) PDE10AAHRADORA3PARP1ALDH1A1
SCHEMBL9106396 0.85 AHR (0.50) PDE10AAHRCYP11B1CYP11B2EGFR
SCHEMBL9108000 0.83 MEN1 (0.47) PDE10AAHRALDH1A1HPGDMEN1
SCHEMBL9105396 0.83 CYP11B1 (0.46) PDE10AAHRMEN1MAPTKMT2A
SCHEMBL9108923 0.83 HSD17B2 (0.48) PDE10AAHRADORA3ALDH1A1ADORA2A
SCHEMBL19167338 0.80 PDE10A (0.60) PDE10AAHRADORA3MAPTNPC1
SCHEMBL15173331 0.80 PDE10A (0.53) PDE10AAHRADORA3NPC1RAB9A
SCHEMBL15173097 0.80 PDE10A (0.53) PDE10AAHRADORA3PARP1MEN1
SCHEMBL9107248 0.80 AHR (0.79) PDE10AAHRADORA3NPC1RAB9A
SCHEMBL9104238 0.80 DYRK1A (0.47) PDE10AAHRADORA3ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2649070-B1 TRIAZOLOPYRIDINE COMPOUNDS HOFFMANN LA ROCHE (CH) 2014-09-17 — — EP claimed
EP-2649070-A1 TRIAZOLOPYRIDINE COMPOUNDS F.HOFFMANN-LA ROCHE AG (CH) 2013-10-16 — — EP claimed
US-8349824-B2 Triazolopyridine compounds HOFFMANN-LA ROCHE INC. (US) 2013-01-08 — — US claimed
WO-2012076430-A1 TRIAZOLOPYRIDINE COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2012-06-14 — — WO claimed
US-20120142665-A1 TRIAZOLOPYRIDINE COMPOUNDS HOFFMANN-LA ROCHE INC. 2012-06-07 — — US claimed
US-20260076950-A1 USE OF A PHOSPHODIESTERASE 10 INHIBITOR FOR THE TREATMENT OF TOURETTE SYNDROME NOEMA PHARMA AG (CH) 2026-03-19 — — US disclosed
US-12544364-B2 Use of a phosphodiesterase 10 inhibitor for the treatment of tourette syndrome NOEMA PHARMA AG (CH) 2026-02-10 — — US disclosed
US-20240390339-A1 USE OF A PHOSPHODIESTERASE 10 INHIBITOR FOR THE TREATMENT OF TOURETTE SYNDROME NOEMA PHARMA AG (CH) 2024-11-28 — — US disclosed
US-11883385-B2 Use of a phosphodiesterase 10 inhibitor for the treatment of tourette syndrome NOEMA PHARMA AG (CH) 2024-01-30 — — US disclosed
EP-4284381-A1 METHODS FOR THE TREATMENT OF CHILDHOOD-ONSET FLUENCY DISORDER Noema Pharma AG (CH) 2023-12-06 — — EP disclosed
US-20230381193-A1 METHODS FOR THE TREATMENT OF CHILDHOOD-ONSET FLUENCY DISORDER NOEMA PHARMA AG (CH) 2023-11-30 — — US disclosed
US-20230149372-A1 USE OF A PHOSPHODIESTERASE 10 INHIBITOR FOR THE TREATMENT OF TOURETTE SYNDROME NOEMA PHARMA AG (CH) 2023-05-18 — — US disclosed
US-8349824-B2 Triazolopyridine compounds HOFFMANN-LA ROCHE INC. (US) 2013-01-08 — — US disclosed
US-8349824-B2 Triazolopyridine compounds HOFFMANN-LA ROCHE INC. (US) 2013-01-08 — — US disclosed
US-8349824-B2 Triazolopyridine compounds HOFFMANN-LA ROCHE INC. (US) 2013-01-08 — — US disclosed
WO-2012076430-A1 TRIAZOLOPYRIDINE COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2012-06-14 — — WO disclosed
WO-2012076430-A1 TRIAZOLOPYRIDINE COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2012-06-14 — — WO disclosed
US-20120142665-A1 TRIAZOLOPYRIDINE COMPOUNDS HOFFMANN-LA ROCHE INC. 2012-06-07 — — US disclosed
US-20120142665-A1 TRIAZOLOPYRIDINE COMPOUNDS HOFFMANN-LA ROCHE INC. 2012-06-07 — — US disclosed
US-20120142665-A1 TRIAZOLOPYRIDINE COMPOUNDS HOFFMANN-LA ROCHE INC. 2012-06-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11883385-B2 Use of a phosphodiesterase 10 inhibitor for the treatment of tourette syndrome PDE2A, PDE3A, PDE5A PDE10A 4/4885AHR 4601/4885ADORA3 3169/4885
US-20240390339-A1 USE OF A PHOSPHODIESTERASE 10 INHIBITOR FOR THE TREATMENT OF TOURETTE SYNDROME PDE2A, PDE3A, PDE5A PDE10A 4/4885AHR 4601/4885ADORA3 3169/4885
US-20230149372-A1 USE OF A PHOSPHODIESTERASE 10 INHIBITOR FOR THE TREATMENT OF TOURETTE SYNDROME PDE2A, PDE3A, PDE5A PDE10A 4/4885AHR 4601/4885ADORA3 3169/4885
US-12544364-B2 Use of a phosphodiesterase 10 inhibitor for the treatment of tourette syndrome PDE10A, PDE11A, PDE1A PDE10A 1/4885AHR 4645/4885ADORA3 3064/4885
US-20120142665-A1 TRIAZOLOPYRIDINE COMPOUNDS PDE5A, PDE3A, PDE3B PDE10A 7/4885AHR 4111/4885ADORA3 132/4885
US-20230381193-A1 METHODS FOR THE TREATMENT OF CHILDHOOD-ONSET FLUENCY DISORDER PDE10A, PDE4A, PDE7B PDE10A 1/4885AHR 4477/4885ADORA3 1891/4885
US-20260076950-A1 USE OF A PHOSPHODIESTERASE 10 INHIBITOR FOR THE TREATMENT OF TOURETTE SYNDROME PDE10A, PDE11A, PDE3A PDE10A 1/4885AHR 4668/4885ADORA3 2302/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.